SG11201811590RA - [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds - Google Patents

[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

Info

Publication number
SG11201811590RA
SG11201811590RA SG11201811590RA SG11201811590RA SG11201811590RA SG 11201811590R A SG11201811590R A SG 11201811590RA SG 11201811590R A SG11201811590R A SG 11201811590RA SG 11201811590R A SG11201811590R A SG 11201811590RA SG 11201811590R A SG11201811590R A SG 11201811590RA
Authority
SG
Singapore
Prior art keywords
international
road
biocon
princeton
route
Prior art date
Application number
SG11201811590RA
Inventor
Alaric J Dyckman
Dharmpal S Dodd
Tasir Shamsul Haque
Louis J Lombardo
John E Macor
Christopher P Mussari
Laxman Pasunoori
Kumar Sreekantha Ratna
Trevor C Sherwood
Shoshana L Posy
Ramesh Kumar Sistla
Subramaya Hegde
Anupama Ramachandra
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SG11201811590RA publication Critical patent/SG11201811590RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property :::` , Organization MD 1101111 II DOI HIM 011101 0 011111 HH11111111111111111111111111 International Bureau (10) International Publication Number (43) International Publication Date .....•\"\"- WO 2018/005586 Al 04 January 2018 (04.01.2018) W I PO I PCT (51) International Patent Classification: dra Industrial Area IV Phase, Jigani Link Road, Bommasan- C07D 471/04 (2006.01) A61K 31/437 (2006.01) dra, Karnataka, Bangalore 560 099 (IN). HEGDE, Subra- (21) International Application Number: maya; c/o Syngene International Limited, Biocon Special Economic Zone, Biocon Park, Plot No. 2&3, Bommasan- PCT/US2017/039633 dra Industrial Area IV Phase, Jigani Link Road, Bommasan- (22) International Filing Date: dra, Karnataka, Bangalore 560 099 (IN). RAMACHAN- 28 June 2017 (28.06.2017) DRA, Anupama; c/o Syngene International Limited, Bio- con Special Economic Zone, Biocon Park, Plot No. 2&3, (25) Filing Language: English Bommasandra Industrial Area IV Phase, Jigani Link Road, (26) Publication Language: English Bommasandra, Karnataka, Bangalore 560 099 (IN). (30) Priority Data: (74) Agent: VANATTEN, Mary K. et al.; Bristol-Myers 201611022328 29 June 2016 (29.06.2016) IN Squibb Company, Route 206 and Province Line Road, 15/635,055 27 June 2017 (27.06.2017) US Princeton, New Jersey 08543 (US). (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY (81) Designated States (unless otherwise indicated, for every [US/US]; Route 206 and Province Line Road, Princeton, kind of national protection available): AE, AG, AL, AM, New Jersey 08543 (US). AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, — (72) Inventors: DYCKMAN, Alaric J.; c/o Bristol-Myers DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, HN, Squibb Company, Route 206 and Province Line Road, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, Princeton, New Jersey 08543 (US). DODD, Dharmpal KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, S.; c/o Bristol-Myers Squibb Company, Route 206 and MG, MK, MN, MW, MX, MY, MZ, NA, NG, NL NO, NZ, Province Line Road, Princeton, New Jersey 08543 (US). OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, HAQUE, Tasir Shamsul; c/o Bristol-Myers Squibb Com- SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, pany, Route 206 and Province Line Road, Princeton, New TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. — = = _ Jersey 08543 (US). LOMBARDO, Louis J.; c/o Bris- tol-Myers Squibb Company, Route 206 and Province Line (84) Designated States (unless otherwise indicated, for every Road, Princeton, New Jersey 08543 (US). MACOR, John kind of regional protection available): ARIPO (BW, GH, E.; 55 Commanders Drive, Washington Crossing, Pennsyl- GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, vania 18977 (US). MUSSARI, Christopher P.; c/o Bris- UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, tol-Myers Squibb Company, Route 206 and Province Line TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Road, Princeton, New Jersey 08543 (US). PASUNOORI, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, Laxman; c/o Syngene International Limited, Biocon Spe- MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, cial Economic Zone, Biocon Park, Plot No. 2&3, Bom- TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, masandra Industrial Area IV Phase, Jigani Link Road, Bom- KM, ML, MR, NE, SN, TD, TG). = = = — = = = masandra, Karnataka, Bangalore 560 099 (IN). RATNA KUMAR, Sreekantha; c/o Syngene International Limit- Declarations under Rule 4.17: = ed, Biocon Special Economic Zone, Biocon Park, Plot No. — as to applicant's entitlement to apply for and be a granted _ 2&3, Bommasandra Industrial Area IV Phase, Jigani Link patent (Rule 4.17(ii)) = Road, Bommasandra, Karnataka, Bangalore 560 099 (IN). — as to the applicant's entitlement to claim the priority of the = SHERWOOD, Trevor C.; c/o Bristol-Myers Squibb Com- earlier application (Rule 4.17(iii)) = — pany, Route 206 and Province Line Road, Princeton, New — of inventorship (Rule 4.17(iv)) = Jersey 08543 (US). POSY, Shoshana L.; c/o Bristol-My- Published: = ers Squibb Company, Route 206 and Province Line Road, — with international search report (Art. 21(3)) Princeton, New Jersey 08543 (US). SISTLA, Ramesh Ku- mar; c/o Syngene International Limited, Biocon Special _ Economic Zone, Biocon Park, Plot No. 2&3, Bommasan- 1-1 of (54) kir) kir) Title: [1,2,4]TRIAZOLO[1,5-A]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS (IR \ , 4, rn (57) : Disclosed are compounds of Formula (I) or a salt thereof, wherein R 1 , R 2 , R 3 , © ...... © GC R 3 , Nom../. R i , R s R4, R 5 , m, n, and p are defined herein. Also disclosed are methods of using such compounds \ 2 ) P •••-•, \ -I- as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compo- 1-1 I , , sitions comprising such compounds. These compounds are useful in treating inflammatory 0 *-- ..- . - ..„^-N H and autoimmune diseases. N ( 5)° N (I) C
SG11201811590RA 2016-06-29 2017-06-28 [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds SG11201811590RA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201611022328 2016-06-29
US15/635,055 US10071079B2 (en) 2016-06-29 2017-06-27 [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
PCT/US2017/039633 WO2018005586A1 (en) 2016-06-29 2017-06-28 [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

Publications (1)

Publication Number Publication Date
SG11201811590RA true SG11201811590RA (en) 2019-01-30

Family

ID=60805851

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811590RA SG11201811590RA (en) 2016-06-29 2017-06-28 [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds

Country Status (31)

Country Link
US (8) US10071079B2 (en)
EP (1) EP3478682B1 (en)
JP (1) JP6995067B6 (en)
KR (1) KR102473482B1 (en)
CN (1) CN109641895B (en)
AR (1) AR108905A1 (en)
AU (1) AU2017287902B2 (en)
BR (1) BR112018077119A2 (en)
CA (1) CA3029620A1 (en)
CL (1) CL2018003821A1 (en)
CO (1) CO2019000686A2 (en)
CY (1) CY1124514T1 (en)
DK (1) DK3478682T3 (en)
EA (1) EA037530B1 (en)
ES (1) ES2886964T3 (en)
HR (1) HRP20211261T8 (en)
HU (1) HUE056091T2 (en)
IL (1) IL263961B (en)
LT (1) LT3478682T (en)
MX (1) MX2018015422A (en)
MY (1) MY196474A (en)
PE (1) PE20190324A1 (en)
PL (1) PL3478682T3 (en)
PT (1) PT3478682T (en)
RS (1) RS62292B1 (en)
SG (1) SG11201811590RA (en)
SI (1) SI3478682T1 (en)
TW (1) TWI636053B (en)
UY (1) UY37310A (en)
WO (1) WO2018005586A1 (en)
ZA (1) ZA201900571B (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
AU2017307208B2 (en) 2016-07-30 2021-01-21 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
EP3510024B1 (en) 2016-09-09 2021-11-17 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
BR112019007450A2 (en) 2016-10-14 2020-07-07 Precision Biosciences, Inc. modified meganucleases specific for recognition sequences in the hepatitis b virus genome
WO2019028301A1 (en) * 2017-08-04 2019-02-07 Bristol-Myers Squibb Company [1,2,4]TRIAZOLO[4,3-a]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS
ES2909401T3 (en) 2017-08-04 2022-05-06 Bristol Myers Squibb Co Substituted Indole Compounds Useful as Inhibitors of TLR7/8/9
WO2019099336A1 (en) * 2017-11-14 2019-05-23 Bristol-Myers Squibb Company Substituted indole compounds
SG11202005513TA (en) * 2017-12-15 2020-07-29 Bristol Myers Squibb Co Substituted indole ether compounds
AU2018390543A1 (en) * 2017-12-19 2020-08-06 Bristol-Myers Squibb Company 6-azaindole compounds
EA202091483A1 (en) 2017-12-19 2020-10-28 Бристол-Маерс Сквибб Компани AMIDE-SUBSTITUTED INDOLIC COMPOUNDS SUITABLE AS TLR INHIBITORS
SG11202005696YA (en) * 2017-12-19 2020-07-29 Bristol Myers Squibb Co Substituted indole compounds useful as tlr inhibitors
WO2019123340A1 (en) 2017-12-20 2019-06-27 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
SG11202005694RA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Amino indole compounds useful as tlr inhibitors
SG11202005733QA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Diazaindole compounds
US11420958B2 (en) 2017-12-20 2022-08-23 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
EP3752505B1 (en) 2018-02-12 2023-01-11 F. Hoffmann-La Roche AG Novel sulfone compounds and derivatives for the treatment and prophylaxis of virus infection
CN111788204B (en) 2018-02-26 2023-05-05 吉利德科学公司 Substituted pyrrolizine compounds as inhibitors of HBV replication
US10870691B2 (en) 2018-04-05 2020-12-22 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis B virus protein X
CA3093888A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
TW202005654A (en) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2'2'-cyclic dinucleotides
TWI818007B (en) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-cyclic dinucleotides
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
TW202014193A (en) 2018-05-03 2020-04-16 捷克科學院有機化學與生物化學研究所 2’3’-cyclic dinucleotides comprising carbocyclic nucleotide
US11713327B2 (en) 2018-06-12 2023-08-01 Hoffmann-La Roche Inc. Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
CN112585134A (en) * 2018-06-13 2021-03-30 豪夫迈·罗氏有限公司 Pyridyl heterocyclyl compounds for the treatment of autoimmune diseases
EP3826724B1 (en) 2018-07-23 2022-10-05 F. Hoffmann-La Roche AG Novel piperazine compounds for the treatment of autoimmune disease
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020048583A1 (en) 2018-09-04 2020-03-12 F. Hoffmann-La Roche Ag Benzothiazole compounds for the treatment of autoimmune diseases
CN112654618A (en) 2018-09-06 2021-04-13 豪夫迈·罗氏有限公司 Novel cyclic amidine compounds for the treatment of autoimmune diseases
WO2020086505A1 (en) * 2018-10-24 2020-04-30 Bristol-Myers Squibb Company Substituted indole dimer compounds
US20210403468A1 (en) * 2018-10-24 2021-12-30 Bristol-Myers Squibb Company Substituted indole and indazole compounds
LT3873903T (en) 2018-10-31 2024-05-10 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
CA3116347A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
JP7350872B2 (en) 2019-03-07 2023-09-26 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． 3'3'-cyclic dinucleotide and its prodrug
TWI751516B (en) 2019-04-17 2022-01-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
TW202212339A (en) 2019-04-17 2022-04-01 美商基利科學股份有限公司 Solid forms of a toll-like receptor modulator
JP2022532568A (en) * 2019-05-07 2022-07-15 ブリストル－マイヤーズ スクイブ カンパニー Prodrug compound
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN110146631B (en) * 2019-06-25 2021-11-12 山西康宝生物制品股份有限公司 Method for detecting residual quantity of polyethylene glycol monomethyl ether in medicinal material
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
CN117843811A (en) 2019-09-30 2024-04-09 吉利德科学公司 HBV vaccine and method of treating HBV
WO2021067657A1 (en) * 2019-10-04 2021-04-08 Bristol-Myers Squibb Company Substituted carbazole compounds
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
TW202200161A (en) 2020-03-20 2022-01-01 美商基利科學股份有限公司 Prodrugs of 4’-c-substituted-2-halo-2’-deoxyadenosine nucleosides and methods of making and using the same
JP2023530264A (en) 2020-06-11 2023-07-14 ブリストル－マイヤーズ スクイブ カンパニー TLR7 inhibitors in combination with prednisolone or hydroxychloroquine to treat cutaneous lupus erythematosus
BR112022025920A2 (en) 2020-06-22 2023-01-10 Bristol Myers Squibb Co TREATMENT OF RHEUMATOID ARTHRITIS
TW202214632A (en) * 2020-07-27 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 Indole fused ring derivatives, their preparation method and medical use
WO2022111636A1 (en) 2020-11-26 2022-06-02 江苏恒瑞医药股份有限公司 Fused tricyclic compound, preparation method therefor and application thereof in medicine
IL307203A (en) 2021-04-16 2023-11-01 Gilead Sciences Inc Thienopyrrole compounds
JP2024518558A (en) 2021-05-13 2024-05-01 ギリアード サイエンシーズ， インコーポレイテッド Combination of TLR8 Modulating Compounds with Anti-HBV siRNA Therapeutics
CN113416188B (en) * 2021-05-31 2022-12-13 河南偶联生物科技有限公司 Synthetic method of [1,2,4] triazolo [1,5-A ] pyridine compound
CA3220923A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (en) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 Diacylglycerol Kinase Modulating Compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022298639A1 (en) 2021-06-23 2023-12-07 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2024015825A1 (en) 2022-07-13 2024-01-18 Bristol-Myers Squibb Company Processes for preparing 5-bromo-3,4-dimethylpyridin-2-amine and 6-bromo-7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridine

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6867200B1 (en) 1998-12-18 2005-03-15 Axys Pharmaceuticals, Inc. (Hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
EA200600069A1 (en) 2003-06-20 2006-08-25 Коли Фармасьютикал Гмбх LOW-MOLECULAR ANTAGONISTS OF TOLL-SIMILAR RECEPTORS (TLR)
WO2006113458A1 (en) * 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
AU2007234399A1 (en) 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
DE102006033109A1 (en) 2006-07-18 2008-01-31 Grünenthal GmbH Substituted heteroaryl derivatives
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
ATE495743T1 (en) 2006-12-01 2011-02-15 Galapagos Nv TRIAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF DEGENERATIONAL AND INFLAMMATORY DISEASES
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
FR2926556B1 (en) * 2008-01-22 2010-02-19 Sanofi Aventis N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
EP2350032B1 (en) 2008-09-26 2016-05-25 Eisai R&D Management Co., Ltd. Benzoxazole compounds and methods of use
CA2738929A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
RU2011137419A (en) 2009-02-11 2013-03-20 Суновион Фармасьютикалз Инк. REVERSE AGONISTS AND HISTAMINE H3 ANTAGONISTS AND WAYS OF THEIR APPLICATION
KR20120035183A (en) 2009-06-10 2012-04-13 선오비온 파마슈티컬스 인코포레이티드 Histamine h3 inverse agonists and antagonists and methods of use thereof
TWI462920B (en) * 2009-06-26 2014-12-01 葛萊伯格有限公司 Novel compound useful for the treatment of degenerative and inflammatory diseases
EP2453895B1 (en) 2009-07-16 2018-05-23 Mallinckrodt LLC (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
US9241991B2 (en) 2010-10-21 2016-01-26 The Brigham And Women's Hospital, Inc. Agents, compositions, and methods for treating pruritus and related skin conditions
PL2663555T4 (en) 2011-01-12 2017-08-31 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
PL2663550T4 (en) 2011-01-12 2017-07-31 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
CA2837207A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
RU2606114C2 (en) 2011-06-01 2017-01-10 Джейнус Байотерапьютикс, Инк. Novel immune system modulators related applications
KR101913619B1 (en) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Novel compounds as modulators of gpr-119
WO2013009140A2 (en) 2011-07-13 2013-01-17 Sk Chemicals Co., Ltd. 2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors
CA2850932A1 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
TWI619704B (en) 2012-05-18 2018-04-01 大日本住友製藥股份有限公司 Carboxylic acid compounds
JO3407B1 (en) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd Tetrahydropyrazolopyrimidine Compounds
AU2014334554B2 (en) 2013-10-14 2018-12-06 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US9643967B2 (en) 2013-12-13 2017-05-09 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as TLR inhibitors
EP3398948A3 (en) 2014-08-22 2018-12-05 Janus Biotherapeutics, Inc. 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
EP3334745B1 (en) 2015-08-13 2024-05-15 Merck Sharp & Dohme LLC Cyclic di-nucleotide compounds as sting agonists
IL263934B2 (en) 2016-06-29 2023-10-01 Hanmi Pharm Ind Co Ltd Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
SG11201811507YA (en) 2016-06-29 2019-01-30 Kezar Life Sciences Crystalline salts of peptide epoxyketone immunoproteasome inhibitor
AU2017307208B2 (en) 2016-07-30 2021-01-21 Bristol-Myers Squibb Company Dimethoxyphenyl substituted indole compounds as TLR7, TLR8 or TLR9 inhibitors
EP3510024B1 (en) 2016-09-09 2021-11-17 Bristol-Myers Squibb Company Pyridyl substituted indole compounds
ES2909401T3 (en) 2017-08-04 2022-05-06 Bristol Myers Squibb Co Substituted Indole Compounds Useful as Inhibitors of TLR7/8/9
WO2019028301A1 (en) 2017-08-04 2019-02-07 Bristol-Myers Squibb Company [1,2,4]TRIAZOLO[4,3-a]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS
WO2019099336A1 (en) 2017-11-14 2019-05-23 Bristol-Myers Squibb Company Substituted indole compounds
SG11202005513TA (en) 2017-12-15 2020-07-29 Bristol Myers Squibb Co Substituted indole ether compounds
US10544143B2 (en) 2017-12-18 2020-01-28 Bristol-Myers Squibb Company 4-azaindole compounds
EA202091483A1 (en) 2017-12-19 2020-10-28 Бристол-Маерс Сквибб Компани AMIDE-SUBSTITUTED INDOLIC COMPOUNDS SUITABLE AS TLR INHIBITORS
SG11202005696YA (en) 2017-12-19 2020-07-29 Bristol Myers Squibb Co Substituted indole compounds useful as tlr inhibitors
AU2018390543A1 (en) 2017-12-19 2020-08-06 Bristol-Myers Squibb Company 6-azaindole compounds
SG11202005733QA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Diazaindole compounds
US11420958B2 (en) 2017-12-20 2022-08-23 Bristol-Myers Squibb Company Aryl and heteroaryl substituted indole compounds
SG11202005694RA (en) 2017-12-20 2020-07-29 Bristol Myers Squibb Co Amino indole compounds useful as tlr inhibitors
US20210403468A1 (en) 2018-10-24 2021-12-30 Bristol-Myers Squibb Company Substituted indole and indazole compounds

Also Published As

Publication number Publication date
USRE49931E1 (en) 2024-04-23
ES2886964T3 (en) 2021-12-21
EP3478682B1 (en) 2021-07-21
AU2017287902B2 (en) 2021-09-16
UY37310A (en) 2018-01-02
US20180000790A1 (en) 2018-01-04
US20180325874A1 (en) 2018-11-15
PL3478682T3 (en) 2021-12-13
RS62292B1 (en) 2021-09-30
TWI636053B (en) 2018-09-21
WO2018005586A1 (en) 2018-01-04
BR112018077119A2 (en) 2019-04-02
ZA201900571B (en) 2020-10-28
MX2018015422A (en) 2019-04-22
AU2017287902A1 (en) 2019-02-14
CL2018003821A1 (en) 2019-04-22
US10912766B2 (en) 2021-02-09
USRE49880E1 (en) 2024-03-26
USRE49893E1 (en) 2024-04-02
CY1124514T1 (en) 2022-07-22
HRP20211261T1 (en) 2021-11-26
CN109641895B (en) 2021-09-03
AR108905A1 (en) 2018-10-10
PE20190324A1 (en) 2019-03-05
US10478424B2 (en) 2019-11-19
JP6995067B2 (en) 2022-01-14
KR102473482B1 (en) 2022-12-01
MY196474A (en) 2023-04-13
EP3478682A1 (en) 2019-05-08
TW201805285A (en) 2018-02-16
US20230255941A1 (en) 2023-08-17
US20200038374A1 (en) 2020-02-06
CO2019000686A2 (en) 2019-02-19
SI3478682T1 (en) 2021-10-29
US10071079B2 (en) 2018-09-11
US11672780B2 (en) 2023-06-13
LT3478682T (en) 2021-09-27
CN109641895A (en) 2019-04-16
US20210085651A1 (en) 2021-03-25
PT3478682T (en) 2021-09-15
EA037530B1 (en) 2021-04-08
IL263961B (en) 2021-01-31
HRP20211261T8 (en) 2022-01-21
KR20190022735A (en) 2019-03-06
CA3029620A1 (en) 2018-01-04
HUE056091T2 (en) 2022-01-28
EA201990048A1 (en) 2019-05-31
DK3478682T3 (en) 2021-09-13
JP6995067B6 (en) 2023-12-14
IL263961A (en) 2019-01-31
JP2019523241A (en) 2019-08-22

Similar Documents

Publication Publication Date Title
SG11201811590RA (en) [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
SG11201900619XA (en) Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
SG11201900077QA (en) 1,3-dihydroxy-phenyl derivatives useful as immunomodulators
SG11201804098TA (en) Purinones as ubiquitin-specific protease 1 inhibitors
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201807301SA (en) Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors
SG11201807980QA (en) Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer
SG11201804934PA (en) Novel Compounds
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201407710VA (en) Compositions comprising short-acting benzodiazepines
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201908786VA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201806485RA (en) Pyrrolobenzodiazepine conjugates
SG11201908465QA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201804589TA (en) Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201810429UA (en) Anti-cd19 antibody formulations
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201807540UA (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
SG11201402986RA (en) Kinase inhibitors
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases